Condition: Thrombocytopenia, Neonatal Alloimmune · Sponsor: Janssen Research & Development, LLC
The purpose of this study is to evaluate the effectiveness of nipocalimab compared with placebo in reducing the risk of severe fetal and neonatal alloimmune thrombocytopenia (FNAIT).
This description comes directly from the study's public registry record.
Study Contact · 844-434-4210 · Participate-In-This-Study1@its.jnj.com
Always discuss trial participation with your own doctor first.
| Universitair Ziekenhuis Leuven | Leuven, Belgium | Recruiting |
| Instituto de Medicina Integral Professor Fernando Figueira | Recife, Brazil | Recruiting |
| Instituto D Or de Pesquisa e Ensino IDOR | Rio de Janeiro, Brazil | Recruiting |
| Hospital Das Clinicas Da Faculdade De Medicina Da USP | São Paulo, Brazil | Recruiting |
| CHRU Lille | Lille, France | Recruiting |
| Hopital trousseau- APHP | Paris, France | Recruiting |
| Semmelweis Egyetem | Budapest, Hungary | Recruiting |
| Sheba Medical Center | Ramat Gan, Israel | Recruiting |
| Mangiagalli Clinic IRCCS Ca Granda Foundation Ospedale Maggiore Policlinico | Milan, Italy | Recruiting |
| Fondazione Policlinico Universitario A Gemelli IRCCS | Rome, Italy | Recruiting |
| Haukeland University Hospital | Bergen, Norway | Recruiting |
| Oslo University Hospital HF Ulleval sykehus | Oslo, Norway | Recruiting |
+ 9 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06449651